Welcome to our dedicated page for Exact Sciences SEC filings (Ticker: EXAS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Exact Sciences Corp (NASDAQ: EXAS) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures filed with the U.S. Securities and Exchange Commission. These documents offer detailed information about Exact Sciences’ cancer screening and diagnostic testing business, financial performance, and significant corporate events.
For EXAS, key filings include current reports on Form 8-K that describe material developments. One Form 8-K reports quarterly financial results, including revenue contributions from the Screening grouping, which encompasses Cologuard tests and PreventionGenetics, and from the Precision Oncology grouping, which includes global Oncotype DX and therapy selection tests. These filings also discuss non‑GAAP metrics such as adjusted EBITDA, adjusted gross margin, and free cash flow, along with reconciliations and management’s rationale for using these measures.
Another important 8-K details the Agreement and Plan of Merger among Exact Sciences, Abbott Laboratories, and a wholly owned Abbott subsidiary. This filing explains the structure of the proposed merger, the per‑share cash consideration to be paid for Exact Sciences common stock, the treatment of equity awards, the conditions to closing, termination rights, and any potential termination fee. It also notes that Exact Sciences’ board of directors unanimously approved the merger agreement and recommends that stockholders adopt it, subject to customary conditions.
Additional 8-K filings describe a collaboration and license agreement with Freenome Holdings, Inc. for blood‑based colorectal cancer screening tests, as well as other corporate announcements furnished as exhibits, such as earnings press releases and investor communications. These documents provide context on how Exact Sciences is expanding its portfolio in blood‑based screening and multi‑cancer early detection.
On Stock Titan, investors can review these SEC filings as they are made available through EDGAR. AI‑powered tools can help summarize lengthy disclosures, highlight key terms of material agreements, and surface notable changes in guidance, capital structure, or strategic direction, enabling users to quickly understand the implications of new EXAS filings.
Director sale under 10b5-1 plan: A director of Exact Sciences Corp. (EXAS) sold 2,000 shares of common stock on
Exact Sciences (EXAS) reported a proposed sale of 1,500 common shares by an insider through Fidelity Brokerage Services with an aggregate market value of
Exact Sciences (EXAS) filing a Form 144 notifies a proposed sale of 2,000 common shares held by an insider through Fidelity Brokerage Services LLC with an aggregate market value of
The filing also discloses a sale of 1,485 shares on
FMR LLC and Abigail P. Johnson report shared beneficial ownership of 18,588,183.06 shares of Exact Sciences Corp common stock, representing 9.8% of the class. FMR LLC is shown with 17,584,537.69 shares of sole voting power and 18,588,183.06 shares of sole dispositive power. The filing states these securities are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer. An exhibit is referenced for a related 13d-1(k) agreement.
James Edward Doyle, a director of Exact Sciences Corporation (EXAS), reported a sale of company common stock. The Form 4 shows a disposition of 1,485 shares on 08/13/2025 at a reported price of $42.02 per share under a Rule 10b5-1 trading plan established on 03/09/2025. After the sale, the filing reports 59,962 shares beneficially owned by Mr. Doyle. The Form 4 was signed via power of attorney on 08/14/2025.
Exact Sciences (EXAS) submitted a Form 144 notifying a proposed sale of 1,485 shares of common stock through Fidelity Brokerage Services LLC (900 Salem Street, Smithfield, RI 02917) with an aggregate market value of $62,399.70. The securities were acquired on 06/12/2025 by restricted stock vesting and payment is listed as compensation. The approximate date of sale is reported as 08/13/2025, and the filing states there were no securities sold during the past three months by the person for whose account the sale is proposed. The filing also discloses total shares outstanding of 189,319,110 and includes the standard representation that the filer does not know of any undisclosed material adverse information.
FAQ
What is the current stock price of Exact Sciences (EXAS)?
What is the market cap of Exact Sciences (EXAS)?
